author-photo

Arnd Nusch

Praxis

73

Papers

2058

Citations

Citation Trend

Filter By

Papers (73) Sort By

JournalConferenceOthers

91O Pooled analysis of patient (pt)-reported outcomes (PROs) in the MONALEESA (ML)-2, -3, and -7 trials: Additional results and key subgroup findings

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
247P Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptor–positive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS10-16: Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184].

2021 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Abstract PS11-16: Rare patients in routine care: Treatment and outcome in advanced invasive lobular breast cancer in the prospective German research platform OPAL

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Seltene Patientengruppen in der klinischen Routine: Behandlungs- und Outcomedaten von Patientinnen mit invasiv lobulärem, metastasiertem Mammakarzinom aus der prospektiven, deutschen Registerplattform OPAL

2021
Show All
- Source
- Cite
- Save
Citations (0)
Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer

2020
Show All
- Source
- Cite
- Save
Citations (15)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号